(Q33435967)

English

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (English)

1 reference

Europe PubMed Central

4 November 2017

phase I clinical trial

0 references

multicenter clinical trial

0 references

phase II clinical trial

0 references

Filippo de Braud

9

1 reference

Europe PubMed Central

4 November 2017

author name string

Padmanee Sharma

1

1 reference

Europe PubMed Central

4 November 2017

Margaret K Callahan

2

1 reference

Europe PubMed Central

4 November 2017

Petri Bono

3

1 reference

Europe PubMed Central

4 November 2017

Joseph Kim

4

1 reference

Europe PubMed Central

4 November 2017

Pavlina Spiliopoulou

5

1 reference

Europe PubMed Central

4 November 2017

Emiliano Calvo

6

1 reference

Europe PubMed Central

4 November 2017

Rathi N Pillai

7

1 reference

Europe PubMed Central

4 November 2017

Patrick A Ott

8

1 reference

Europe PubMed Central

4 November 2017

Michael Morse

10

1 reference

Europe PubMed Central

4 November 2017

Dung T Le

11

1 reference

Europe PubMed Central

4 November 2017

Dirk Jaeger

12

1 reference

Europe PubMed Central

4 November 2017

Emily Chan

13

1 reference

Europe PubMed Central

4 November 2017

Chris Harbison

14

1 reference

Europe PubMed Central

4 November 2017

Chen-Sheng Lin

15

1 reference

Europe PubMed Central

4 November 2017

Marina Tschaika

16

1 reference

Europe PubMed Central

4 November 2017

Alex Azrilevich

17

1 reference

Europe PubMed Central

4 November 2017

Jonathan E Rosenberg

18

1 reference

Europe PubMed Central

4 November 2017

publication date

9 October 2016

1 reference

Europe PubMed Central

4 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

4 November 2017

17

1 reference

Europe PubMed Central

4 November 2017

1590-1598

1 reference

Europe PubMed Central

4 November 2017

11

1 reference

Europe PubMed Central

4 November 2017

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

The future of immune checkpoint therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

21 June 2018

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

31 October 2018

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5648054

31 October 2018

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930496-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930496-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab Doubles Survival for Patients with HNSCC

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930496-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Confidence limits for probability of response in multistage phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930496-X

7 January 2021

based on heuristic

inferred from DOI database lookup

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930496-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30496-X

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33435967&oldid=1749479242"